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Available online 15 March 2016Electroencephalogram (EEG) data in nonclinical species can play a critical role in the successful evaluation of a
compound during drug development, particularly in the evaluation of seizure potential and for monitoring
changes in sleep. Yet, while non-invasive electrocardiogram (ECG)monitoring is commonly included in preclin-
ical safety studies, pre-dose or post-dose EEG assessments are not. Industry practices as they relate to preclinical
seizure liability and sleep assessments are not well characterized and the extent of preclinical EEG testing varies
between organizations. In the current paper, we discuss the various aspects of preclinical EEG to characterize
drug-induced seizure risk and sleep disturbances, aswell as describe the use of these data in a regulatory context.
An overview of EEG technology—its correct application and its limitations, as well as best practices for setting up
the animal models is presented. Sleep and seizure detection are discussed in detail. A regulatory perspective on
the use of EEG data is provided and, tying together the previous topics is a discussion of the translational aspects
of EEG.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
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A recent survey indicated that most drugs approved in Japan be-
tween 1999 and 2013 with reported adverse drug reactions (ADRs)
classiﬁed as seizures/convulsions in patients were not identiﬁed to
have a seizure liability during preclinical development (Nagayama,
2015). When considering seizure/convulsion observed at any dose,
only 25 out of 105 (23.8%) approved drugs showed concordance of pre-
clinical and clinical data for seizurogenic effects based on ADRs. When
observed in preclinical studies, seizures/convulsions were identiﬁed in
repeat toxicology studies (64%), proconvulsion safety pharmacology
studies (40%) or in other safety pharmacology studies (28%).
Proconvulsion safety pharmacology studies typically include models
aimed to characterize the risk of drug-induced seizures such as EEG
studies to monitor for ictal activity and seizure threshold tests. Other
safety pharmacology studies include a wide range of pharmacology
models (e.g. cardiovascular, respiratory, gastrointestinal and even
other neurological models)which are deﬁned under the ICH S7A guide-
line (U.S. Food and Drug Administration, 2001). Industry practices as.
. This is an open access article underthey relate to preclinical seizure liability assessments are not well char-
acterized and the extent of preclinical seizure liability testing varies be-
tween organizations (Authier et al., 2016). Spontaneous seizures are
reported in various species including rats (Nunn & Macpherson, 1995;
Satomoto et al., 2012) and dogs (Bielfelt, Redman, & McClellan, 1971)
and it is crucial to differential spontaneous seizures from drug-
induced ictal activity. Susceptibility to drug-induced seizures differs be-
tween species (Bassett et al., 2014) but also between age groups
(Himmel, 2008) within the same species rendering translation of pre-
clinical results to humans challenging. Irrespective of the limitations
when using animal models in drug development, preclinical seizure lia-
bility testing strategies aim to succeed at risk identiﬁcation and support
clinical trial risk management.
In a recent survey on preclinical neurotoxicology investigations, a
minority of participants reported using pre-dose electroencephalog-
raphy (EEG) (Authier et al., 2016) to conﬁrm suitability of the
animals for inclusion on study. As technology advances have in-
creased the availability of non-invasive EEG monitoring and analysis
(Pouliot et al., 2015), typical safety testing paradigmsmay need to be
challenged.
Tremors and other behavioral effects such as ataxia, myoclonus or
emesis are often observed in early toxicology investigations such asthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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during drug development as part of the toxicology investigations as de-
ﬁned under the ICH guideline M3(R2) (U.S. Food and Drug
Administration, 2010). Once the MTD is identiﬁed, the drug dose levels
that induce signiﬁcant adverse effects may never be used again in the
organized sequence of preclinical drug safety testing studies. A common
concern when tremors are present is the presence of underlying abnor-
mal EEG activity. Surface ECGmonitoring is commonly included in pre-
clinical toxicology studies but EEG assessments are classically
introduced only once a neurological concern is identiﬁed. Monitoring
EEG duringMTDor repeat dose toxicology studiesmay represent an op-
portunity for early identiﬁcation of a CNS risk. With older patient popu-
lations recognized to have an increased seizure incidence (Vélez &
Selwa, 2003), this concern may be of increased clinical relevance given
the life-threatening consequences of status epilepticus. Beyond
seizurogenic risks, a number of drugs in development may alter sleep
architecture (Rachalski et al., 2014) with potential negative impacts
on the patient population. Selective serotonin reuptake inhibitors
(SSRIs) are widely prescribed but are also associated with sleep distur-
bance (Ferguson, 2001) such as delayed REM sleep onset, increase
awakenings and reduce REM sleep. Here we discuss the various aspects
of preclinical EEG assessments to characterize seizure risk and also in-
vestigate potential drug-induced sleep disturbances.
2. Fundamentals of EEG
To fully appreciate the role of EEG in nonclinical safety evaluation, an
understanding of the fundamentals of the technology is important. The
fundamentals of EEG will detail what underlies the generation of EEG
waves, both from an anatomical and an instrumentation perspective
and will review descriptive versus interpretation of EEG waveform pat-
ters as well as describing typical normal EEG patterns.
2.1. What is EEG?
EEG is the recording of electrical activity from the brain's cortical
surface. Neuronal output is in μV, unlike the mV electrical signals from
recording an ECG, and needs to be ampliﬁed by 106 to be displayed.
Most of the EEG's electrical signal arises from neuronal post-synaptic
potentials (PSP). Action potentials are too small and too short to record.
PSPs can be excitatory (EPSP), causing the post-synaptic neuron to ﬁre,
or can be inhibitory (IPSP), causing the post-synaptic neuron not to ﬁre.
The combination of EPSPs and IPSPs induce current ﬂow around neu-
rons, which is recorded as EEG. The complex neuronal activity frommil-
lions of cortical neurons generates the irregular EEG signal that
translates into seemingly random and changing waveforms (Fig. 1). By
contrast an evoked potential is an integrated signal that is synchronized
by a precipitating stimulus such as a noise or ﬂashing light.
2.2. EEG instrumentation
While a wide range of EEG electrode types can be used
(Galanopoulou et al., 2013), the most common use for nonclinical EEG
is from the cortical surface. This recording can be accomplished using
scalp electrodes in a restrained subject, or by using telemetry, consisting
of surgically implanted electrodes that send signals to a remote receiver.Fig. 1.A single channel of EEG, showing the richmix of frequencies and amplitudes that compris
to-second mix of amplitudes and frequencies, but also shows larger rhythmic oscillations char
oscillations is partially due to the interaction between the thalamus and cortex. It is also basedSpecialized applications may use depth electrodes surgically implanted
into the parenchyma of the brain (frequently into the hippocampus or
thalamus). However obtained, the signal is ampliﬁed, ﬁltered, displayed
and recorded for analysis. Human EEG uses a system of standard place-
ment of scalp electrodes, the 10–20 system (Jasper, 1958). Digital re-
cording from this array allows the data to be displayed in different
montages, which helps in deﬁning abnormal waveforms and in localiz-
ing the source of the abnormality. EEG in nonclinical species such as ro-
dents, a standard electrode placement is not essential while a standard
placement is typically beneﬁcial in larger species (e.g. non-human
primates).
2.3. Interpretation of EEG patterns
For clinical and nonclinical applications, reading and understanding
EEG waveforms is based on a systematic and organized process to rec-
ognize abnormal from normal patterns. Interpretation of a typical
10 second strip of 3-channel EEG from a non-human primate (Fig. 2)
will require an exhaustive investigation of the context in which this ac-
tivity was recorded (Table 1). For pre-seizure detection, the typical pat-
tern is the spike. Spike morphology is generally electro-negative
(deﬂects up ﬁrst), the rise is faster than the fall, it is paroxysmal, is
20–80 msec in duration and is of high voltage: 200–300 μV (Fig. 3). A
precise description is essential when identifying an EEG pattern as nor-
mal or pathological. For example, a 3 Hz spike and wave pattern is clas-
sic ﬁnding in absence seizure (Panayiotopoulos, 1999); 2 Hz spike and
wave typical for a seizure disorder while 6 Hz spike and wave is a nor-
mal EEG variant identiﬁed as “14 and 6 positive spikes” or “ctenoids”
(Bassett et al., 2014; Nidermeyer & Croft, 1961).
A number of normal EEG variants can be mistaken for seizures.
Wickets (Fig. 4) are sharply contoured waves with a rhythmic frequen-
cy at 7–11Hz thatwereﬁrst described by Reiher and Lebel (1977). They
resemble theGreek letter “mu” and are often seen in drowsiness or light
sleep. Wickets may be misdiagnozed as epilepsy (Krauss, Abdallah,
Lesser, Thompson, &Niedermeyer, 2005). Other commonEEGmorphol-
ogies mimicking epileptiform discharges include hyperventilation-
induced slowing, phantom spike-and-wave, hypnagogic and hypno-
pompic hypersynchrony (Azzam & Bhatt, 2014; Benbadis & Tatum,
2003). Increased synchrony (Fig. 5) is common during sleep stage tran-
sitions and hypnagogic and hypnopompic hypersynchrony are consid-
ered normal variants of drowsiness that may be misdiagnozed as
seizure activity. The morphology of rhythmic mid-temporal discharges
(RMTD; previously called psychomotor variant) shows patterns that
are notched and ﬂat-topped, lasting 1–10 s (Fig. 6).
Artifacts are also a major consideration during EEG interpretation. It
is important to distinguish patterns generated from the brain from arti-
facts created by factors outside the CNS. Movement is a frequently seen
artifact, as muscles generate larger voltage signals than do neurons.
Movement artifact is not only from whole body movement but can be
caused by tongue or eye movements. Tongue movements cause the
baseline to undulate. Use of an ocular electrode placed above the eye
can help detect and localize eye movements. Usually, movement arti-
facts affect scalp electrodes more often than implanted telemetry sys-
tem electrodes. One exception in nonclinical species is chewing:
chewing, particularly in monkeys or dogs (Fig. 7A and B), is frequently
seen with EEG telemetry as the animals are free to move around thees the normal EEG, in this example, from a Beagle dog. EEG consists not only of the second-
acterized by slower frequencies. Physiologically, the underlying mechanism of these large
on the intrinsic rhythmic capacity of the large neuronal networks in the cortex.
Fig. 2. EEG from surface electrodes in a non-human primate in the high dose group at 2 h
post-dose; Tmax for this drug is 4 h and the drug is CNS-active.
Fig. 3. Typical spike morphology identiﬁed at EEG.
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ferentiated from EEG by the presence of high frequency and high ampli-
tude electromyographic (EMG) transients with typical crescendo/
decrescendo proﬁles owing to muscular contractions. EMG is not ex-
haustively discussed in the current publication but may be used to as-
sess convulsion, activity level or sleep stages. A wide range of muscle
groups can be monitored in laboratory animals including the temporal
muscles, neckmuscles or limbs. Theuse of temporalmuscles can beuse-
ful in the interpretation of EEG traces from an electrode montage using
the 10–20 system as the EMG activity can be compared to thematching
EEG traces to conﬁrm artifacts. Neck muscles are typically used in sleep
studies (Rachalski et al., 2014). Videomonitoring can also be considered
for interpretation of EEG (Authier et al., 2009). Video-EEG is considered
the gold standard in clinical neurology and similar methodologies can
be applied to safety pharmacology studies.
3. EEG analysis
3.1. qEEG and spectral analysis
Spectral analysis is recognized as a common clinical (Fisher,
Scharfman, & deCurtis, 2014) and preclinical (Bassett et al., 2014) tool
for data analysis for sleep and seizure assessments. EEG signals was ad-
vanced in the 1970s with the advent of qEEG (or quantitative EEG), giv-
ing added clarity and information of EEG signals by analyzing its
patterns using computer and mathematical methods. Fast Fourier
Transform (FFT) can be used to quantify the EEG power across a range
of frequencies (Sterman, 1981). FFT converts the EEG signal to a repre-
sentation of the power (cumulative amplitude) across the range of fre-
quencies (Fig. 8A–D). An increase in higher frequencies can be observed
prior to seizurewith various positive control drugs (Engel, Bragin, Staba,
& Mody, 2009; Zijlmans, Jacobs, Zelmann, Dubeau, & Gotman, 2009).
Conversely, an increase in qEEG powers may also be observed with
drugs that are not seizurogenic such as diazepam (Authier et al.,
2014), highlighting the diversity of qEEG proﬁles which may be
observed.
qEEG changes may differ between brain regions adding to the inter-
pretation considerations. The use of frontal, parietal and/or occipital
EEG derivation(s) needs to be weighted in the selection of the preclini-
cal EEGmodel given the limitations generally caused by hardware spec-
iﬁcations but also cranial anatomy in some species. EEG derivations thatTable 1
Generic questions to address during EEG interpretation.
Is the pattern present during drug treatment and/or baseline?
If during treatment only, when does it occur post-dose?
How does this timing relate to the pharmacokinetics of the drug?
Are there any concommitant behavioral abnormalities?
What is the frequency (Hz) and amplitude (μV) of the pattern?
What is the morphology of the wave in comparison to surrounding traces?
Does it occur over the top of normal rhythm or does it disrupt normal rhythm?
Does it occur in complexes or singly?
Is the pattern continuous or transient?
Does the pattern recur?are located in the midline sagittal plane are often preferred to conduct
qEEG investigations in all laboratory species due to the limited cranial
muscles present at this level therefore minimizing the interferences
caused by electromyographic (EMG) activity.
Social interactions and circadian cycle are key considerations in the
study design of qEEG studies. Comparison of time-matched qEEG data
from control and treated periods from the same animal can be used to
evaluate potential drug effects. Interactions with congeners are highly
beneﬁcial to the animals butwill also alter qEEGparameters. In this con-
text, a drug inducing signiﬁcant effects on the behavior of an animal in
the room may affect the qEEG proﬁle of all animals in the same room
as communication between individuals occurs. To avoid bias caused
by pharmacologically modiﬁed behavioral interactions, a qEEG study
design would typically involve dosing on different days or in different
rooms on the same day.
Like most physiological parameters, qEEG is highly inﬂuenced by the
circadian cycle and proper interpretation usually relies on comparison
of data captured precisely at the same time of the day in the same animals
(Authier et al., 2012). Owing to circadian cycle effects, a qEEG cross-over
designwill often control the dosing timebut husbandry and feeding activ-
ities should also be completed precisely at the same time of the day for all
treatment sessions. As for most other telemetry studies, the presence of
the technical personnel in the room should be avoided when planning
qEEG analysis. In large animal species, maintaining the same technical
personnel throughout the study will also increase data stability given
the potential stress associated with a new caretaker. Despite a wide
range of factors that need to be controlled inpreclinical qEEG, spectral anal-
ysis remains one of themost sensitive endpoint with direct applicability in
safety pharmacology studies and safety assessments with the ability to
identify low amplitude effects with a limited number of individuals.
3.2. Automated or manual EEG analysis in the assessment of seizurogenic
effects
Software for automated seizure detection on pre-clinical EEG traces
are typically designed to identify spikes trains (Authier et al., 2009)
while epilepsy detection algorithms available for patient EEG allow for
detection of ictal and interictal traces (Acharya, Sree, Swapna, Martis,Fig. 4. Example of human EEG showing wickets in the ﬁrst and third traces.
Fig. 5. Increased synchrony in EEG from a freely moving cynomolgus monkey using implanted telemetry.
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vidual speciﬁc and also vary depending on the electrode montage used.
To account for these variations, it is generally useful to adapt the detec-
tion algorithm to the experimental conditions that are used.While spike
train detection is an important aspect of EEG analysis, a plethora of
other changes may be indicative of a seizure risk and manual review
of EEG traces by an electroencephalographer is usually an important
part of the analysis. Abnormal EEG activitymay occurwith concomitant
clinical signs and systematic review of EEG traces at times when clinical
signs were noted is often appropriate. For seizure activity mediated via
neuronal receptors or other concentration dependent mechanisms, the
abnormal EEG activity may exhibit an incidence distribution correlated
with higher plasma and CNS tissue exposure. Pre-deﬁned manual re-
view of EEG traces distributed over the monitoring period based on
the expected pharmacokinetics (PK) of the compound can be relevant
and increase sensitivity to detect abnormal EEG activity or biomarkers
of increased seizure risk.4. Non-clinical sleep assessments
Preclinical sleep assessment is gaining rising importance in the ad-
vancement of a pharmaceutical candidate as drug companies recognize
the value of translatable biomarkers that not only are predictive of efﬁ-
cacy but can also demonstrate engagement of its intended target aswell
as detect adverse events early on in the drug discovery process. In addi-
tion, the evaluation of sleep has been used as an endpoint to discover
novel therapies for insomnia (Winrow et al., 2011) and epilepsy as
well as a diagnostic for sleep disorders. Assessing sleep early on in
drug discovery has become important not only when considering the
economic burden of sleep loss ($100 billion US; Stoller, 1994) but
with the aging population, polypharmacy is more common and sleep
disruptions due to a new medication would almost certainly decrease
compliance with long term treatment. Sleep architecture is well studied
in all species, including humans, and many of its features areFig. 6. Example of human EEG showing rhythmic mid-temporal discharges (RMTD)(R:
right side, L: Left side).remarkably similar frommouse toman,making EEG one of only a hand-
ful of highly translatable central nervous system biomarkers (Ivarsson,
2009; Paterson, Nutt, & Wilson, 2011; Veasey et al., 2000).
The assessment of sleep stages is referred to as polysomnography,
which requires the electrophysiological collection of up to three core
measures. EEG measures the spontaneous electrical activity over single
or multiple brain regions while electromyogram (EMG)measures mus-
cular electrical activity, and electrooculogram(EOG) assesses eyemove-
ments. Biopotential activity of these core measures can be detected in
animals with surgically implanted electrodes implanted over the cortex
(known as ECoG or electrocorticogram) for chronic sleep stage assess-
ments and for frequency changes (see below). This method offers 24-
hr/7-day EEG data collection, including temperature, locomotor activity
andheart rate, all while the animal is free to roam in its home cagewith-
out any tethering limiting movement. The combination of these mea-
sures is used to deﬁne individual sleep stages during individual
analysis epochs, usually not greater than 30 s. A trained human EEG
scorer or validated computer algorithm assigns a score of the predomi-
nant sleep pattern within each epoch, using gold standard scoring rules
established by Rechshaffen & Kales in 1968 (Rechtschaffen & Kales,
1968) and recently updated by the American Academy of Sleep Medi-
cine (AASM) in 2007 (Iber, Ancoli-Israel, Chesson, & Quan, 2007). The
overall sleep architecture can then be determined from the collection
of individual scoring epochs over the duration of the recording or during
a period of interest.
Wake patterns are easily recognized by the trained eye by the pres-
ence of desynchronized, high frequency, low amplitude EEG, increased
muscle tone and rapid eye movements. Sleep patterns are broken
down into three distinct non-REM stages (termed N1, N2 and N3) and
REM sleep (rapid eye movement), each marked with distinct features
that help deﬁne them. N1 is a transitionary stage into falling asleep,
marked by low voltage EEG and the beginning of slow eye movements.
N2 has moderate voltage EEG with the introduction of sleep spindles
and K-complexes. As the individual progresses into N3, increased syn-
chrony occurs in EEG as delta waves appear, voltage is high and as
such this stage is deﬁned as “slow wave or delta sleep”. REM sleep is
characterized by EEG that is desynchronized (as in wake butwith a pre-
dominance of theta power) while muscle tonemeasured by EMG regis-
ters atonia, and EOG measures the appearance of distinct bursts of
characteristic eye movements (Iber et al., 2007). Consolidated, diurnal
sleepers such as non-human primates and humans, normally cycle
throughout the various non-REM stages during their sleep phase before
ultimately reaching REM sleep. EEG/EMG/activity are assessed in poly-
phasic rodents (transition rapidly through sleep stages) typically by
assigning sleep stages to either active wake, quiet sleep, deep sleep or
REM sleep (Toth & Bhargava, 2013). EOG activity is typically not
Fig. 7. A. Chewing artifact at EEG recorded with telemetry in a freely moving jacketed Beagle dog B. Chewing artifact at EEG recorded with telemetry in a freely moving cynomolgus
monkey.
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maintain long term in this species.
qEEG has been shown to be a powerful and dynamic tool, as bursts
(or power) of sinusoidal waves have been linked to certain mental
states such as sedation or stimulation and have even been validated as
a biomarker for disorders such as ADHD (increased theta-beta power
ratio) (Leiser, Dunlop, Bowlby, & Devilbiss, 2011). Recent innovative
drug discovery approaches have compared frequency changes relative
to vehicle within certain sleep stages, allowing for better comparisons
to standard of care treatments for sleep disorders such as insomnia
(Fox et al., 2013). EEGpatterns consist ofﬁve basic frequencies, alternat-
ing between states of increased and decreased synchrony within the
signal, dependent on the sleep pattern the animal is in at the time of
measurement. At its slowest frequency and most synchronized state,
delta activity is detected and ranges between 0.5–4 Hz and is associated
with deep sleep. With increased frequency and desynchrony, delta is
terminated and transitions into theta activity (4–8 Hz). Theta activity
is often associated with REM sleep. Alpha activity (8–12 Hz) is readily
seen in relaxed or quiet wakefulness. Sigma activity (12–16 Hz) is typ-
ically present in the awake state. Frequencies greater than 16 Hz are re-
ferred to as beta (16–30 Hz) and gamma (N30 Hz) and are detected
during active mental activity (Jobert et al., 2012). As a general rule,Fig. 8. A. Fast Fourier Transform (FFT) on EEG (Cz–Oz) from a telemetered cynomolgus monkey
200 mV). B. Fast Fourier Transform (FFT) on EEG (Cz–Oz) from a cynomolgus monkey during
from 0 to 70 mV). C. Fast Fourier Transform (FFT) on EEG (Cz–Oz) from a cynomolgus monke
axis from 0 to 70 mV). D. Fast Fourier Transform (FFT) on EEG (Cz–Oz) from a cynomolgus m
from 0 to 70 mV).the cumulative absolute amplitude as calculated by FFT at lower fre-
quencies (e.g. delta) will be lower than values for higher frequencies
(e.g. beta or gamma). Hence, pharmacological evaluations typically
rely on relative changes within a given power band (Bassett et al.,
2014).
Typical study designs for the assessment of sleep architecture/fre-
quency changes in animals involve evaluating the core measures
(qEEG only requires EEG) asmentioned above with the potential exclu-
sion of periods with high EMG activities. Chronic dosing studies prefer-
ably involve pre-screening animals in order to power studies with
animals that have high quality EEG/EMG/EOG signals, good baseline cir-
cadian patterns and are void of paroxysmal EEG activity. After baseline
activity has been assessed, animals are assigned to a chronic, multiple
day dosing regimenwith either a parallel or cross-over design (random-
ly assigned to drug ﬁrst or vehicle ﬁrst treatment and then crossed over
to the opposite regime). Cross-over studies are preferable, as each ani-
mal can act as their own control when a manipulation (drug or some
other treatment) is compared to a negative control (either vehicle or
sham). The use of genetically manipulated mice and rats or knockouts
can add value to pharmacological experiments as they can demonstrate
the dependence of the drug's effects on a given target or gene product in
animals with a targeted genetic disruption. Knockouts serve as theirduring generalized seizurewith a peak amplitude at 6 Hz (Graph amplitude axis from 0 to
the post-ictal period with signiﬁcant attenuation of all frequencies (Graph amplitude axis
y during deep sleep (stage N3) with an increase in lower frequencies (Graph amplitude
onkey during active wake with an increase in higher frequencies (Graph amplitude axis
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individuals.
Other than drug exposure, several factors can impact sleep architec-
ture. Factors such as increased stress, illness, and changes in social/
physical environment(s) have been shown to be disruptive to normal
physiological circadian patterns (Bruse et al., 2012; Irvine, White, &
Chan, 1997). EEG studies in animals should aim to keep extraneous, un-
controlled factors at a minimum. Normal and uncontrollable changes
during sleep include changes in respiratory drive which may induce
changes to sleep patterns. With the increased incidence of diagnosis of
sleep apnea and an aging population enduring polypharmacy, sleep
studies undertaken early in drug development can protect patients
down the line who are already at risk for sleep issues. EEG studies
done preclinically can also inform on efﬁcacy, qualify normal EEG activ-
ity and identify potential adverse events of a drug (and ultimately affect
prescription rate down the line), as well as outline risks associated with
sleep loss and changes in sleep, making it an extremely powerful tool to
assess brain activity. While some methodological & analytical differ-
ences do exist when assessing EEG in animals vs. humans, the sleep/
wake systems in the brain are remarkably similar, allowing for translat-
able, pharmacodynamic assessment of pharmaceutical candidates early
on in the drug discovery process.
5. Species differences and interpretation of EEG studies
Differences have been identiﬁed between animal species for the sus-
ceptibility to drug-induced seizure (Bassett et al., 2014). The rank order
between species for seizure susceptibility can differ between com-
pounds but the Beagle dog is often the most susceptible (Elander,
2013) possibly owing to genetic predisposition to idiopathic epilepsy
(Edmonds et al., 1979). Cases for which the Beagle dog was less suscep-
tible than other species were also reported (Authier, unpublished data)
and careful and conservative interpretation of the preclinical data is al-
ways warranted. Within an animal model, inter-individual differences
can be observed for anticonvulsant (Bankstahl, Bankstahl, & Löscher,
2012; Brandt, Volk, & Löscher, 2004; Klein, Bankstahl, & Löscher,
2015) and proconvulsant effects (Bassett et al., 2014; Himmel, 2008).
The route of administration can also account for part of the variability
observed in EEG studies with oral dosing typically associated with
greater variations in exposures than parenteral dosing and consequent-
ly increased CNS effect variability.
Decisions on the safety of drugs may be based on a broad range of
considerations including in silicomodeling, receptor afﬁnity, drug expo-
sure, histopathology and/or seizure characteristics (e.g. precursor EEG
changes, precursor clinical signs, seizure onset triggers, duration/self-
limiting, success of emergency treatments in animals, recovery, kindling
effects, inter-individual variability and incidence, species differences,
etc.(Markgraf et al., 2014). In particular, clinical signs in animals may
be correlated with the exhibition of seizures and/or abnormal brain ac-
tivity following drug administration (see Section 8 for further discus-
sion). However, skepticism exists that the exhibition of these signs in
animals does not correlate with signs that are predictive of seizure
and/or brain activity in humans. Therefore, a caveat remains that the se-
quence and drug exposure concentrations at which these precursor
signs of seizure are observed in animal studies may differ from the
human response. Precursor clinical signs of CNS toxicity are often non-
speciﬁc (e.g. tremors, nystagmus, emesis, ataxia) and the mechanisms
involved may also differ between species. While differences can be ob-
served, animal models remain a cornerstone of drug safety testing
prior to ﬁrst in human administration. Similar precursor sign proﬁles
are observed across species with pentylenetetrazol (PTZ), a commonly
used positive control (Bassett et al., 2014) but also for a broader range
of pharmaceutical agents (Easter et al., 2009). Seizure liability studies
often aim to determine the EEG NOEL (No Observed Effect Level) or
NOAEL (NoObserved Adverse Effect Level) in the test system to later es-
timate safe doses for clinical investigations. There is agreement amongthe authors that plasma concentrations at doses that produce seizures
and/or abnormal brain activity in animals are likely correlated to those
thatmay produce the same effect in humans. Therefore, plasma concen-
trations at the dose estimated as a NOAEL in animals may be used to es-
tablish safetymargins, which are useful when developing a clinical dose
escalation plan and PK dose-stopping criteria (see Section 8 for further
discussion).
6. Seizure risk assessment: Data to consider when assessing seizure
risks
Seizure risk assessmentmay be based on various ﬁndings such as PK
data on the parent drug (and biologically active metabolites), clinical
and anatomical pathology ﬁndings, physiological alterations, and be-
havioral observations. The PK proﬁle(s) should include values for time
to peak concentration (i.e., Tmax), peak concentration (Cmax), overall
systematic exposure (AUC), and elimination half-life (t1/2). Values for
Tmax and t1/2 should be considered when evaluating the time course
for EEG ﬁndings and premonitory signs of convulsions. This consider-
ation may be helpful in determining which chemical is responsible for
inducing seizures and other related toxicities based on the plasma levels
of each chemical at the time these effects occur. Seizures are known to
be induced following alterations in clinical pathology endpoints that in-
clude sodium, calcium, andmagnesium. Also, anatomical changes in the
brain may induce convulsions and seizures (e.g., head injury). With re-
gard to behavior, premonitory signs of convulsions in animals include
head and body tremors, incoordination, and ataxia (Bassett et al.,
2014; Smythe, Ryan, & Pappas, 1988). Although these signs may be re-
lated to convulsions, there are instances in which each may be due to
other pharmacological effects produced by the product. For example,
behaviors such as tremors and shaking may be due to hypothermia.
Note that there is evidence that hyperthermia and hypothermia
can induce seizures in animals (Smythe et al., 1988; van Gassen
et al., 2008; Kallman 2008). EEG can provide a deﬁnitive conﬁrma-
tion of the presence of seizure based on the observation of ictal activ-
ity (i.e. EEG spike train). Clinically, there is no minimum time to
deﬁne a seizure and EEG discharges accompanied by clinical signs
of seizure qualify as an electrographic seizure irrespective of their
duration (Fisher et al., 2014). Overall, the seizure risk assessment
should consist of various types of data to determine if a seizure oc-
curred and, if so, the exposure level of the chemical that induced
this effect.
7. Safety margins: Factors to consider when estimating margins
Although there is an ofﬁcial FDA policy on how to determine safety
margins for the starting dose of initial clinical trials in adult healthy vol-
unteers, the guidance that provides this information does not provide
insight on how to determine safety margins for dose-escalation treat-
ment schedules (see the FDA guidance for industry: Estimating the
Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics
in Adult Healthy Volunteers, available at http://www.fda.gov/
downloads/Drugs/GuidanceComplianceRegulatoryInformation/
Guidances/ucm078932.pdf. The safety evaluation for each drug must
take into consideration the risks and beneﬁts to the intended patient
population. In general, a safety margin of ≥10-fold is usually acceptable
for products that produce irreversible and unmonitorable adverse ef-
fects (e.g. unexplained death, severe anatomical pathology ﬁndings
such as liver necrosis, seizures). A few key factors to consider when es-
tablishing safety margins include patient population, route of adminis-
tration, and drug interactions. Patient populations with increased
vulnerability to convulsions include those with a history of seizures
and/or head injury (Kim et al., 2006; Schierhout and Roberts, 2012).
Also, patient populations with a history of chronic use of alcohol and
other drugsmaydecrease the seizure threshold and increase vulnerabil-
ity to convulsions (Enevoldson, 2004;Hillbom, Pieninkeroinen, & Leone,
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since seizure vulnerability may be increased in younger patients due to
the underdevelopment of detoxiﬁcation systems and in older patients
given the inefﬁciency of the same systems. In rodents, ﬁndings demon-
strate that spontaneous seizures (e.g., spike wave seizures) increase in
frequency as animals age, which provides further evidence that the
age of subjects is a critical variable in evaluating seizures (Ellens et al.,
2009; Kelly, 2010; Sgro, Benagh, Modlin, & Kallman, 2006; Sitnikova,
Hramov, Grubov, & Koronovsky, 2014). The route of administration is
considered since the absorption of the product may vary depending
on the route employed. For example, drugs administered intravenously
(IV) are entirely bioavailable (i.e. 100%), whereas those that are admin-
istered via other routes may not be. The absorption of drugs via these
other routes may be highly variable across patients, which adds uncer-
tainty to themargin needed to ensure safety. In regard to potential drug
interactions, safetymargins greater than 10-foldmay need to be appro-
priatewhen the test product is co-administeredwith a proconvulsant or
convulsant agent.
8. Examples when nonclinical EEG studies can help determine safe
clinical exposure levels
Drugs effects may represent biological responses that occur sponta-
neously in organisms and that overlap temporally. Also, the potency in
which a drug (and its metabolites) produces an effect may vary across
species, resulting in the observation of different levels of sensitivity to
the drug. These issues complicate the interpretation of ﬁndings across
animal species in which convulsions and abnormal brain activity (in-
cludes seizures) are observed. Therefore, the scenarios discussed
below illustrate the use of EEG techniques to determinewhether clinical
signs and convulsions were due to abnormal brain activity that is drug-
related and to establish the most sensitive and/or relevant species. The
goal of any toxicology study is to deﬁne doses that are appropriate to
study in humans and to avoid unwanted side effects. This is completed
by both deﬁning a NOEL/NOAEL and the exposure levels at which unac-
ceptable adverse effects occur. The scenarios below illustrate the use of
exposure levels in the most sensitive and/or relevant species to estab-
lish PK dose-stopping criteria for clinical studies. In the scenarios
discussed, EEG techniques are used to establish exposure levels at
which abnormal brain activity (includes seizures) is not observed at ei-
ther the NOEL or NOAEL estimated in animals. These levels are used to
establish PK dose-stopping criteria that set the top clinical exposure
levels (i.e., for Cmax and/or AUC) at 1/10 that measured at either the
NOEL or NOAEL estimated in the most sensitive and/or relevant animal
species. This approach is used given the nature of the toxicity of concern
(abnormal brain activity) and to help ensure that the toxicity is not ob-
served in patients, especiallywhen the beneﬁts of treatment do not out-
weigh the risks associated with it. Note that the scenarios do not
represent ﬁndings from an actual study report. These scenarios were
written to illustrate challenges thatmay arisewhen evaluatingpotential
therapeutics that may be seizurogenic agents that do not signiﬁcantly
alter clinical pathology endpoints. The conclusions provided are from
the perspective of the authors and represent one of many approaches
to interpreting the ﬁndings provided.
As mentioned above, convulsions may occur spontaneously in ani-
mals. EEG studies offer a deﬁnitive means to determine if clinical signs
such as convulsions or other premonitory signs are due to abnormal
brain activity or not. This can be complicated by the background inci-
dence of convulsions in the species tested. For example, Drug A (0, 20,
100, or 500 mg/kg) is administered IV to dogs in a single-dose toxicolo-
gy study. DrugA is known to produce hypothermia and sedation inmul-
tiple species. In the current study, dogs exhibit hypoactivity at
≥100 mg/kg; tremors across all doses; and a convulsion at 500 mg/kg
(high dose). The convulsion is exhibited in a dog that exhibited tremors.
Given the observation of tremors in this animal it is considered a poten-
tial premonitory sign of convulsions in the low and mid dose groups.Therefore, a NOAEL cannot be established since a convulsion was ob-
served at the high dose and tremors are exhibited across the doses test-
ed. This scenario is challenging since the incidence of convulsions was
low and in a species known to exhibit spontaneous convulsions
(Bielfelt et al., 1971) and the tremors observed may have simply been
secondary to hypothermia. This information suggests that the convul-
sionmay not be drug related andwarrants further EEG testing. In a sep-
arate study, drug naive dogs exhibit tremors, in the absence of abnormal
EEG activity at the doses previously tested. The convulsion is not
reproduced in a second study and EEG data suggest no evidence of ab-
normal brain activity in the presence of premonitory signs. These data
support the conclusion that the convulsion observed in the initial
study may have been spontaneous given its low incidence and the
lack of abnormal EEG activity in treated dogs.
In scenarios in which abnormal brain activity is detected via EEG
techniques, PK dose- stopping criteria can be established for the clinic
based on plasma levels of drug in the most sensitive species. For exam-
ple, Drug B is orally administered to rats (0, 1, 10, or 17mg/kg) and dogs
(0, 0.5, 2.5, or 5mg/kg). Based on PK data, the oral bioavailability of Drug
B ranges from 10 to 70% and the excretion of unchanged drug in urine
samples appears complete (100%) across species. Both species exhibit
convulsions at the highest dose tested. Given the observation of shaking
and uncoordinated behavior at the high dose group both signs were
considered premonitory signs of convulsion in animals from the low-
and mid-dose groups that exhibit them. A NOAEL cannot be estimated
in either species since convulsions are observed at the high dose and
premonitory signs are exhibited across the doses tested. The highly var-
iable oral bioavailability confounds the determination of themost sensi-
tive species based on body surface area comparisons. As a follow-up,
Drug B (same doses) is evaluated in rats and dogs using EEG techniques
in order to correlate the ﬁndings with exposure data. In rats, abnormal
EEG activity is observed at the high dose and characterized by the ap-
pearance of high frequency gamma activity, repetitive bursts of sharp
waves, and increased sharp waves. In dogs, abnormal EEG activity is ob-
served at the mid- and high-dose and is characterized by the appear-
ance of high frequency gamma activity at the high dose and repetitive
bursts of sharp waves and increased sharp waves at the mid and high
dose. Across species, abnormal EEG activity is observed at 1 h following
treatment, which correlates with the averaged Tmax value for Drug B.
There is no evidence of frank seizure in either species at the doses test-
ed. A NOEL can be estimated in rats and dogs, respectively, at 10 mg/kg
and 0.5mg/kg based on the lack of abnormal EEG activity at these doses.
The use of EEG techniques provides a deﬁnitive evaluation of alterations
in CNS activity, which in turn allows for a more informed decision as to
whether or not the premonitory signs exhibited are associated with ab-
normal brain activity. Overall, the dog is deemed themost sensitive spe-
cies given that the Cmax value at its NOEL (333 ng/mL) was lower than
that in rats (555 ng/mL).
PK dose-stopping criteria can be established based on the NOEL in
dogs, given the nature of the toxicities that deﬁne it. The PK dose-
stopping criteria establish the top Cmax value allowed in the clinic. The
top value (33.3 ng/mL) is set 10-fold lower than the exposure level at
the NOEL in the dog given the marked variability in the oral absorption
of the drug and the nature of the toxicity of concern (i.e., abnormal brain
activity). This scenario illustrates that premonitory signs such as shak-
ing and uncoordinated activitymay be indicative of abnormal EEG activ-
ity in animals; however, these signs do not always correlate with EEG
abnormalities. Also, ﬁndings in the dog demonstrate that abnormal
EEG activity occurs at exposure levels of drug that are lower than
those at which frank convulsions occur.
EEG data can also be useful in evaluating drugs with a different met-
abolic proﬁle in the test species compared to humans, a scenario that is
not always straightforward in terms of how to appropriately establish
safety margins to inform clinical dose-escalation limitations. As such,
being able to correlate the appearance of abnormal EEG activity with
the Tmax of a parent or major metabolite can provide valuable data to
Fig. 9. Cmax plasma levels for preclinical toxicology data — a compound that produces
tremor, seizures and brain lesions.
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orally administered to monkeys, dogs, and rats. Convulsions are ob-
served in these species following the administration of Drug C, which
is known to form a biologically active metabolite M123. Comparison
of the drug/metabolite ratio in the nonclinical test species to humans
may help determine which animal species may be the most relevant
In this example, the metabolite was formed in dogs and monkeys, but
not rats and themetabolic proﬁle in themonkeymost closely resembles
that of humans. As all species exhibited convulsions, theparent is clearly
contributing to the convulsions, however, the role of the metabolite, if
any, in the convulsions noted is still not clear.
As a follow-up, Drug C and the isolatedM123metabolite is evaluated
inmonkeys using EEG techniques to determine if abnormal EEG activity
is induced by one or both compounds. Evidence of frank seizure and ab-
normal EEG activity is observed inmonkeys at themid and high dose of
Drug C, conﬁrming that the observed convulsions are indeed seizures.
Frank seizure and abnormal EEG activity are also observed following
treatment with the M123 alone, demonstrating that both compounds
must be considered seizurogenic. A NOEL for Drug C is estimated at
2mg/kg (Cmax= 22 ng/mL) based on evidence of abnormal EEG activ-
ity and frank seizure at higher doses. A NOEL could not be established
for M123 given the abnormal EEG activity and frank seizure observed
at the dose tested. However, these data provide reasonable justiﬁcation
that the monkey can be used to establish real-time PK dose-stopping
criteria based on the parent exposure levels alone, given the compara-
bility of the metabolic proﬁle with humans. Therefore, the top clinical
Cmax was established at 2.2 ng/mL for the parent drug as this plasma
level takes into account both the parent and metabolite levels. If the
metabolic proﬁle was not comparable to humans, stopping criteria
would have to take into consideration both the parent and themetabo-
lite Cmax.
This scenario illustrated that the most relevant animal species may
be determined based on the metabolite proﬁle in the species tested,
the isolated metabolite should be tested alone to evaluate its effects
on EEG activity, and the PK stopping criteria should include top expo-
sure levels for the parent drug and metabolites demonstrated to pro-
duce abnormal EEG activity and other adverse effects. A risk
assessment should be determined for both the parent drug and its bio-
logically active metabolites. This assessment should be based on ﬁnd-
ings from studies that evaluate the parent drug and its biologically
active metabolites alone and in combination. Doses of the metabolite
should be selected to ensure exposure levels comparable to that ob-
served following treatment with the doses of parent drug tested in
order to ensure the evaluation of relevant exposure levels. The Tmax
values for both the parent and its metabolites should be compared to
the time points in which adverse effects such as abnormal EEG activity
are observed in order to understand the potential role of these chemical
entities in the effects measured following treatment. The interaction of
the parent drug and its metabolite may be complex and result in differ-
ent pharmacological and toxicological proﬁles. Therefore, these results
must be carefully interpreted, especially when used to establish PK
dose-stopping criteria.
9. Translation of non-clinical EEG to the clinic
Translation of EEG ﬁndings to the clinical environment makes the
critical impact on the regulatory environment. Other measures of con-
vulsive alterations such as proconvulsive assessments, where the
novel new drug is combined with a known convulsant like picrotoxin,
kainic acid, electroshock, pentylenetetrazol, or prior electrical kindling
to determine changes in threshold are useful preclinical tools that lack
direct translation to the clinic. An indirect ranking of the convulsive lia-
bility of compounds may be possible but these same paradigms are not
conducted with human subjects since all of them depend on establish-
ing convulsion prior to adding the new drug to the paradigm. Essential-
ly, how can these preclinical assessments support human safety and thedesign of clinical evaluations of newpharmaceuticals? The primary pre-
clinical assessment tool that can bemonitored in humans is EEG. Several
factors must be considered in the quality of preclinical EEG for human
translation and safety evaluations. The major issues that must be con-
sidered are species differences, age differences in EEG, EEG assessment
tools, and the limitations of predictability from preclinical assessment
to the clinical environment.
The ﬁrst approach in understanding translation is making a distinc-
tion between reported observations of convulsion from seizures or the
alteration in the electrical activity patterns distinguished from EEG re-
cordings. Typically the goal would be to avoid convulsion by establish-
ment of a same dose or identiﬁcation of premonitory effects that
would aid in the avoidance of convulsive doses of the new compound.
For a premonitory event to be useful in managing a clinical drug trial
the event must occur at lower doses that do not produce convulsions/
seizures or be separated from the convulsive/seizure event by a long pe-
riod of time. Potential premonitory events cannot be an aura to the sei-
zure which indicates that the seizure is eminent since these aura events
do not provide sufﬁcient time to abate the seizure. Fig. 9 illustrates how
clinical signs, other toxicity indicators, and plasma drug level can be
used to put a seizure effect into perspective. Timeframe can be an im-
portant variable for monitoring delayed onset seizures with repeated
dosing and the data generation approach tomonitor delayed onset con-
vulsions and Cmax driven convulsions would be quite different. See
Table 2 for a summary of differences between acute and chronic EEG
monitoring methods. For the delayed onset events, EEG in the non-
precipitated situationmay change overtime prior to the onset of seizure
events (Carfagna, Sgro, Arezzo, & Kallman, 2010; Kallman, 2006). Alter-
ations in muscular endpoints including myoclonus (Kojovic, Cordivari,
& Bhatia, 2011) can be easily deﬁned as convulsion by observers. Incor-
rect labeling of thesemuscular events as convulsion is frequent and can
only be corroborated by EEGmonitoring. The distinction betweenmus-
cular changes and actual EEG spike activity dramatically affect the clin-
ical understanding of these effects. Similarly, drug induced catalepsy
may be incorrectly deﬁned as convulsion (Bricker, Sampson, &
Ablordeppey, 2014; Heitz & Bence, 2013; Sanberg, Bunsey, Giordano,
& Norman, 1988; Winters, Ferrar-Allado, Guzman-Flores, & Alcaraz,
1972), again with EEG serving as a key biomarker for proper identiﬁca-
tion of the drug induced effect.
Once a true seizure proﬁle has been identiﬁed the ﬁnding should be
put into perspective to improve clinical safety. Many drugs used thera-
peutically have seizure proﬁles at therapeutic doses (Alper, Schwartz,
Kolts, & Khan, 2007). Typically the seizure proﬁle for clinical compounds
is observed at the higher doses, with long term use of the drug, and in
patients with a history or predisposition to seizure prior to drug admin-
istration. The most critical factors to understand for translation is the
margin of the seizurogenic effect to the therapeutic dose, establishing
a NOEL/NOAEL, understanding the pre-seizure events that would be re-
liably monitored, the therapeutic endpoint, and whether the effect is
Cmax driven or has a delayed onset. All of these preclinical variables
would impact the design of clinical testing and the probability of drug
development success in the clinic.
The consistency of the observation of convulsions/seizures should be
evaluated across species. Sometimes a compound has a unique
Table 2
Comparison of preclinical acute and chronic EEG recordings.
Acute EEG Chronic EEG
▶ No surgical implantation ▶ Surgical implantation/surface or deep
electrodes
▶ No mapping of sites ▶ Can map sites
▶ Restrained animal ▶ No restraint
▶ Short duration recording ▶ 24/7 up to 3 months or more
▶ Identiﬁcation of seizure activity/-
spiking no qEEG or staging
▶ Identiﬁcation of seizure activity/spiking,
pharmaco-EEG, qEEG, staging
▶ More diagnostic rather than time
expansive
▶ Focus on time expansive recordings
Table 3
Pros and cons of using screening EEGs on large animal studies.
Advantages of EEG Prescreens Disadvantages of EEG Prescreens
• Dogs may have a high rate of convul-
sion at the time of receipt from
suppliers – Reported as 4% (Arezzo
2005) and as 0.02% based on the ven-
dor database
• Not as useful in rodents where the inci-
dence is lower (less than 1%) and rodent
strain is an issue
• Can be incorporated into an ongoing
toxicology study
• May have to conduct additional studies
to understand special population
sensitivity
• Few Ns in large animal toxicology
studies (typically 3–6/treatment
group)
• Although humans are typically not
prescreened they could be to establish a
clinical safety margin
• Special population preclinical data
can be obtained later in drug
development, if required, in a sepa-
rate study
• May have to understand later issues relat-
ed to special sensitivity of therapeutic
population since humans on later clinical
trials may be less homogeneous than ani-
mal population
• Early goal is to understand threshold
or NOAEL under consistent conditions
• Additional cost to toxicology studies –
may require additional animals for
exclusion
• Consistency of population for making
decisions for early healthy subject
safety trials
• Must develop exclusion criteria
• Prescreens for other endpoints on
toxicology studies is based on the idea
of healthy animals concept
• Not a good prescreen requirement for
all toxicology studies but rather for
cause or expected proﬁle
• Can distinguish changes due to drug
exposure in non-epileptic animals
• Cannot detect more subtle qEEG chang-
es but seizure activity only in
prescreens
• Initial Phase 1 clinical studies are fo-
cused on normal or healthy clinical
population
• Might be incorrectly applied when in-
terested in EEG effects other than
threshold determinations
• Supportive of studies designed to de-
termine if observational convulsions
are seizures or due to motoric chang-
es. Baseline EEG must be normal to
make this determination
• Requires high quality expertise
Table 4
Differences between preclinical and clinical EEG recordings.
Preclinical Clinical
• Acute recordings in restrained
animals
• Holter monitoring and acute scalp elec-
trodes in resting state
• Telemetry recordings in surgically
prepared animals
• Multiple sites
• Usually 1–2 general sites on brain
surface
• Limited to therapeutic doses for evaluation
• Deep electrode for evaluation of
hippocampal theta in sleep
evaluation
• Video-EEG considered as gold standard
• Can evaluate dose higher than
therapeutic doses
• Coincidental EMG for signs not possible
• Can record simultaneous video and
EMG
• Conﬁdence in identiﬁcation of seizure/pre--
seizure activity but less conﬁdence in qEEG.
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could be associated with convulsive behavior. Most toxicology pro-
grams include a rodent and large animal species which is usually the
dog. As one ascends the phylogenetic scale there aremore sophisticated
mechanisms to inhibit seizures as a result of increased cortical inhibi-
tion and enhanced reduction in the spread of electrical excitation from
hemisphere to hemisphere characteristic of convulsive proﬁles. An ob-
servation of convulsion in the rat may not be corroborated in the dog
or primate (Kallman, Sgro, Markgraf, & Ballering, 2014). The primate
brain, organization of the cortex, corpus callosum and descending regu-
lation of CNS stimulation is most like the human (Katz, Lasek, & Silver,
1983) but many times not the species of choice for more detailed toxi-
cology evaluations where pharmacokinetics, metabolite proﬁle, and
other toxicological effects are well described in GLP studies. As previ-
ously discussed, the dog offers some special considerations since this
species is frequently selected for characterizing toxicity but is recog-
nized to present a higher rate of seizure proﬁles prior to drug treatment
(Bielfelt et al., 1971). Some laboratories have resorted to prescreening
dogs prior to the start of toxicology studies where there is an indication
that convulsion/seizure is a potential safety issue. These are conducted
on restrained dogs by a short (e.g. 2–10 min) acute EEG recording
with surface needle electrodes to determine if seizure activity or abnor-
mal EEG morphologies is present. Table 3 lists the major pros and cons
of prestudy screening applied to non-clinical studies. The application
to the toxicology study, i.e. pre-FHD or pre-Phase 3 clinical testing,
may impact the decision to apply prescreening.
A ﬁnal consideration is to contrast data from preclinical to clinical
EEG evaluations. Table 4 lists the technical differences between the an-
imal and human approaches for recording. The two approaches can pro-
vide different levels of sensitivity for detection with the human
approach generally considered as more sophisticated and often of lon-
ger duration since a continuous recording approach is commonly
used. When the focus is on seizure activity and not qEEG characteriza-
tion the human and animal data are more consistent and less variable
than when qEEG characterization is of interest.
10. Discussion
EEG appears to be underutilized in non-clinical drug safety testing.
Epidemiological considerations weight for an increasing importance of
CNS safety issues owing to the aging population and growing preva-
lence of polypharmacy. Seizure and sleep liabilities are manifest appli-
cations of EEG to safety testing of drug candidates but challenges
remain in the use of this methodology including data interpretation,
translation from animals to the clinic and drug safety proﬁle variants.
Interpretation challenges originate from the abundance of data but
also from the inherent diversity of EEGmorphologies that can be obtain-
ed.Mechanisms to explain drug induced adverse effects are often poorly
characterized which adds to the uncertainty during seizure risk assess-
ment using animal data. As discussed, thorough characterization of
pharmacokinetics can inform species comparisons with the goal of
predicting thehuman response. Someagents induce adverse CNS effects
after acute administration while others require chronic exposure.Tachyphylaxis, a decrease in the response to a drug, is commonly ob-
servedwith CNS active drugs andmay impact the design of EEG studies.
During toxicology studies, tremors (involuntary symmetrical oscilla-
tions of a body part), myoclonus (brief, involuntary muscle jerk caused
by abrupt muscle contraction) and convulsions (abnormal, violent and
involuntary contraction or series or contractions of the muscles) may
be observed. Each of these observations may be associated with EEG
biomarkers of increased seizure risk or frank ictal activity. EEGmonitor-
ing is essential for proper characterization of the clinical events that are
observed. As a well-established diagnostic methodology, EEG monitor-
ing has the potential to offer a high translational value but a complex
matrix of scientiﬁc and regulatory considerations is involved during
decision-making leading to the inclusion of this neurological monitor-
ing endpoint in preclinical studies. From design to interpretation, the
284 S. Authier et al. / Journal of Pharmacological and Toxicological Methods 81 (2016) 274–285drug development team is faced with multiple aspects to integrate as
they exercise the art of safety pharmacology.
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